Prothena Co. plc (NASDAQ:PRTA) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its position in shares of Prothena Co. plc (NASDAQ:PRTA) by 1.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 864,833 shares of the biotechnology company’s stock after acquiring an additional 10,783 shares during the period. Dimensional Fund Advisors LP owned about 1.61% of Prothena worth $11,980,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Wellington Management Group LLP increased its stake in Prothena by 22.8% during the fourth quarter. Wellington Management Group LLP now owns 5,130,876 shares of the biotechnology company’s stock valued at $71,063,000 after purchasing an additional 952,088 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Prothena by 11.5% during the 4th quarter. Vanguard Group Inc. now owns 1,403,838 shares of the biotechnology company’s stock valued at $19,443,000 after buying an additional 144,737 shares during the last quarter. Federated Hermes Inc. grew its position in shares of Prothena by 84.3% during the 4th quarter. Federated Hermes Inc. now owns 746,177 shares of the biotechnology company’s stock valued at $10,335,000 after buying an additional 341,274 shares during the last quarter. Finepoint Capital LP raised its stake in Prothena by 51.6% during the fourth quarter. Finepoint Capital LP now owns 657,071 shares of the biotechnology company’s stock worth $9,100,000 after acquiring an additional 223,600 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Prothena by 93.7% in the fourth quarter. JPMorgan Chase & Co. now owns 387,350 shares of the biotechnology company’s stock worth $5,365,000 after acquiring an additional 187,364 shares during the last quarter. 97.08% of the stock is owned by institutional investors and hedge funds.

Prothena Trading Up 4.6 %

Prothena stock opened at $7.43 on Friday. The company’s 50-day moving average price is $11.10 and its two-hundred day moving average price is $13.60. The stock has a market cap of $399.93 million, a price-to-earnings ratio of -3.23 and a beta of 0.11. Prothena Co. plc has a 52 week low of $6.92 and a 52 week high of $25.42.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.20). The company had revenue of $2.83 million for the quarter, compared to analyst estimates of $8.18 million. Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. Prothena’s revenue was up 5500.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.34) EPS. Research analysts expect that Prothena Co. plc will post -4.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on PRTA shares. Piper Sandler upped their target price on Prothena from $94.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Oppenheimer upped their price objective on Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a research note on Friday, February 7th. JMP Securities cut their target price on Prothena from $80.00 to $78.00 and set a “market outperform” rating on the stock in a research note on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research report on Friday, February 21st. Finally, StockNews.com upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research report on Monday, February 24th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $51.71.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.